The prevention of cognitive decline and dementia is a major public health priority. The Memory and Aging Project (MAP) has made considerable progress elucidating the complex relationships between risk factors, common neuropathologies and resilience markers that increase or decrease the rate of cognitive decline, and risk of dementia. In nearly 200 peer-reviewed manuscripts, we reported genetic, medical, experiential, and psychological factors associated with increased or decreased rates of cognitive decline and dementia risk. We reported that Alzheimer's, vascular, and Lewy body pathologies (AD, CVD, LBD) explain about 40% of the variation of cognitive decline, and that resilience markers (e.g., cortical presynaptic proteins and locus coeruleus neurons) were associated with a slower rate of decline accounting for 8% of the variation, and that many risk factors with little direct relation o pathologies or resilience markers accounted for >10% of the variation of decline, controlling for pathologies. Additional factors related to cognitive decline await discovery. The overall goal of the planned continuation of MAP is to discover additional proteins associated with the slope of cognitive decline, after accounting for the effects of common pathologies. We use the term """"""""residual cognitive decline"""""""" to describe this innovative primary study outcome. Methods to interrogate the genome, and therefore, the proteome, have improved markedly over the past decade, making the discovery of proteins that underlie cognitive decline both timely and feasible. We plan to continue collecting clinical and post-mortem data on MAP participants.
Aim 1, Discovery and Verification Phase, will combine """"""""omics-wide"""""""" association studies with innovative integrative pathway analyses on genomic, epigenomic, and transcriptomic data from human brain from 500 MAP participants to discover proteins associated with residual cognitive decline;it will select 200 proteins for quantitation in human brain to verify that protein level i associated with residual cognitive decline.
Aim 2, Validation Phase, will quantify the 200 proteins selected and verified in Aim 1 with a new sample of 350 brains from MAP participants that will accrue by the end the funding period, followed by a joint statistical analysis to increas power (n=850).
Aim 3 will link the validated proteins to the wealth of available risk factor data t discover novel biologic pathways linking risk factors to cognitive decline and dementia. Our plan is supported by extensive and compelling new preliminary data that demonstrate its high likelihood of success and demonstrate that the study is innovative, high yield and low risk. The continuation of MAP will discover additional proteins associated with cognitive decline and novel biologic pathways linking risk factors to cognitive decline. These proteins will represent either unknown pathologies that increase rates of cognitive decline or resilience markers that decrease rates of cognitive decline. Both sets of proteins will offer new therapeutic targets for the prevention and treatment of cognitive decline and dementia. Thus, the study has the potential to have a high and sustained impact on aging and dementia research.
The prevention of cognitive decline, MCI and dementia is a major public health priority. The proposed continuation of MAP will discover additional proteins associated with cognitive decline and novel biologic pathways linking risk factors to cognitive decline, MCI and dementia. These proteins, representing unknown pathologies and resilience markers associated with faster and slower rates of cognitive decline, will offer new therapeutic targets for the prevention and treatment of cognitive decline, MCI and dementia.
|Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-20|
|Buchman, Aron S; Yu, Lei; Boyle, Patricia A et al. (2016) Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. Neurology 86:735-41|
|Han, S Duke; Boyle, Patricia A; Arfanakis, Konstantinos et al. (2016) Financial literacy is associated with white matter integrity in old age. Neuroimage 130:223-9|
|Han, S Duke; Boyle, Patricia A; James, Bryan D et al. (2016) Mild Cognitive Impairment and Susceptibility to Scams in Old Age. J Alzheimers Dis 49:845-51|
|Morris, Martha Clare; Brockman, John; Schneider, Julie A et al. (2016) Association of Seafood Consumption, Brain Mercury Level, and APOE Îµ4 Status With Brain Neuropathology in Older Adults. JAMA 315:489-97|
|Wilson, Robert S; Boyle, Patricia A; Capuano, Ana W et al. (2016) Late-life depression is not associated with dementia-related pathology. Neuropsychology 30:135-42|
|Han, S Duke; Boyle, Patricia A; James, Bryan D et al. (2016) Discrepancies between cognition and decision making in older adults. Aging Clin Exp Res 28:99-108|
|Perlman, Amichai; Shah, Raj C; Bennett, David A et al. (2016) Antihypertensive and Statin Medication Use and Motor Function in Community-Dwelling Older Adults. J Am Med Dir Assoc 17:220-4|
|Chouraki, Vincent; Reitz, Christiane; Maury, Fleur et al. (2016) Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. J Alzheimers Dis 53:921-32|
|Roostaei, T; Nazeri, A; Felsky, D et al. (2016) Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease. Mol Psychiatry :|
Showing the most recent 10 out of 384 publications